AU2002214868A1 - Therapeutic oligonucleotides of reduced toxicity - Google Patents

Therapeutic oligonucleotides of reduced toxicity

Info

Publication number
AU2002214868A1
AU2002214868A1 AU2002214868A AU1486802A AU2002214868A1 AU 2002214868 A1 AU2002214868 A1 AU 2002214868A1 AU 2002214868 A AU2002214868 A AU 2002214868A AU 1486802 A AU1486802 A AU 1486802A AU 2002214868 A1 AU2002214868 A1 AU 2002214868A1
Authority
AU
Australia
Prior art keywords
reduced toxicity
therapeutic oligonucleotides
oligonucleotides
therapeutic
toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214868A
Inventor
Thomas D Madden
Murray S Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inex Pharmaceuticals Corp
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Publication of AU2002214868A1 publication Critical patent/AU2002214868A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
AU2002214868A 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity Abandoned AU2002214868A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24517600P 2000-11-02 2000-11-02
US60/245,176 2000-11-02
PCT/CA2001/001540 WO2002036767A2 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity

Publications (1)

Publication Number Publication Date
AU2002214868A1 true AU2002214868A1 (en) 2002-05-15

Family

ID=22925600

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214868A Abandoned AU2002214868A1 (en) 2000-11-02 2001-10-31 Therapeutic oligonucleotides of reduced toxicity

Country Status (5)

Country Link
EP (1) EP1330520A2 (en)
JP (1) JP2004512383A (en)
AU (1) AU2002214868A1 (en)
CA (1) CA2426047A1 (en)
WO (1) WO2002036767A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (en) 1998-05-22 2007-02-28 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
KR101545660B1 (en) * 2008-07-18 2015-08-20 온코제넥스 테크놀로지즈 아이엔씨. Antisense formulation
AU2009320006A1 (en) 2008-10-30 2010-06-03 Peixuan Guo Membrane-integrated viral DNA-packaging motor protein connector biosensor for DNA sequencing and other uses
IL310001A (en) 2021-07-08 2024-03-01 Nippon Shinyaku Co Ltd Precipitation suppressing agent
AU2022306820A1 (en) 2021-07-08 2024-01-04 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
WO2023282344A1 (en) * 2021-07-08 2023-01-12 日本新薬株式会社 Nephrotoxicity reducing agent

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use

Also Published As

Publication number Publication date
EP1330520A2 (en) 2003-07-30
CA2426047A1 (en) 2002-05-10
WO2002036767A3 (en) 2003-01-23
WO2002036767A2 (en) 2002-05-10
JP2004512383A (en) 2004-04-22

Similar Documents

Publication Publication Date Title
AU2002222853A1 (en) Therapeutic compounds
AU2001252135A1 (en) Therapeutic agents
AU2001291859A1 (en) Use of copolycarbonates
AU2001227858A1 (en) Delivery of cardiac constraint jacket
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2002223827A1 (en) Well treatment
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AU2001237992A1 (en) Purification of oligonucleotides
AU2002231206A1 (en) Treatment of depression
AU2001260834A1 (en) The treatment of herpes
AU2001243515A1 (en) Combination drug therapy
AU2002353739A1 (en) Therapeutic compounds
AU2001274877A1 (en) Pest treatment composition
AU2002214868A1 (en) Therapeutic oligonucleotides of reduced toxicity
AU2002217073A1 (en) Spray catheter
AU2001232244A1 (en) Drug comprising combination
AU2001273903A1 (en) Therapeutic agents
AU2001245414A1 (en) Treatment of allergies
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2001275696A1 (en) Therapeutic agent
AU1405001A (en) Treatment of diseases
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis
AU1618901A (en) Treatment of rosacea